"approved"@en . "Meclizine"@en . . . . . . . "569-65-3"@en . . . . . . . . . . . . . . . . . . . . . . . . . . "Meclizine"@en . . . "A histamine H1 antagonist used in the treatment of motion sickness, vertigo, and nausea during pregnancy and radiation sickness. [PubChem]"@en . "U.S. Patent 2,709,169."@en . "Nevidoxine"@en . "Well absorbed"@en . "Take with food to reduce irritation. Avoid alcohol."@en . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . "Along with its actions as an antagonist at H₁-receptors, meclizine also possesses anticholinergic, central nervous system depressant, and local anesthetic effects. Meclizine depresses labyrinth excitability and vestibular stimulation and may affect the medullary chemoreceptor trigger zone."@en . . . "6 hours"@en . . . "Humans and other mammals"@en . . " "@en . . . . . . . . . "Meclozine"@en . . . . . . . . . . . . " "@en . . . . . . . . . . "Symptoms of overdose include drowsiness and anticholinergic effects. LD₅₀=mg/kg (orally in rat)."@en . . "For the prevention and treatment of nausea, vomiting, or dizziness associated with motion sickness."@en . . . . . . . . . . . . . . .